| Autor: |
Colletti SL; Merck Research Laboratories, Merck & Co., Inc., Rahway, New Jersey 07065, USA. steve_colletti@merck.com, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB |
| Jazyk: |
angličtina |
| Zdroj: |
Journal of medicinal chemistry [J Med Chem] 2003 Jan 30; Vol. 46 (3), pp. 349-52. |
| DOI: |
10.1021/jm025585h |
| Abstrakt: |
Imidazo[1,2-a]pyridyl N-arylpyridazinones were hybridized from the classic pyridinylimidazoles and the more recent dual hydrogen bond acceptors, resulting in a new structural class of selective p38 MAP kinase inhibitors. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
